^
Association details:
| Biomarker: | KRAS amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Excerpt:
Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6/10) of the cases.
DOI:
10.1038/nature11156.
